Convolutional Neural Network Based on Fluorescein Angiography Images for Retinopathy of Prematurity Management

Purpose The purpose of this study was to explore the use of fluorescein angiography (FA) images in a convolutional neural network (CNN) in the management of retinopathy of prematurity (ROP). Methods The dataset involved a total of 835 FA images of 149 eyes (90 patients), where each eye was associated with a binary outcome (57 “untreated” eyes and 92 “treated”; 308 “untreated” images, 527 “treated”). The resolution of the images was 1600 and 1200 px in 20% of cases, whereas the remaining 80% had a resolution of 640 and 480 px. All the images were resized to 640 and 480 px before training and no other preprocessing was applied. A CNN with four convolutional layers was trained on 90% of the images (n = 752) randomly chosen. The accuracy of the prediction was assessed on the remaining 10% of images (n = 83). Keras version 2.2.0 for R with Tensorflow backend version 1.11.0 was used for the analysis. Results The validation accuracy after 100 epochs was 0.88, whereas training accuracy was 0.97. The receiver operating characteristic (ROC) presented an area under the curve (AUC) of 0.91. Conclusions Our study showed, we believe for the first time, the applicability of artificial intelligence (CNN) technology in the ROP management driven by FA. Further studies are needed to exploit different fields of applications of this technology. Translational Relevance This algorithm is the basis for a system that could be applied to both ROP as well as experimental oxygen induced retinopathy.

[1]  Stratis Ioannidis,et al.  Evaluation of a deep learning image assessment system for detecting severe retinopathy of prematurity , 2018, British Journal of Ophthalmology.

[2]  Francisco J. Olguin-Manriquez,et al.  New insights in diagnosis and treatment for Retinopathy of Prematurity , 2016, International Ophthalmology.

[3]  Anna L. Ells,et al.  The International Classification of Retinopathy of Prematurity revisited. , 2005, Archives of ophthalmology.

[4]  Michael F Chiang,et al.  Interexpert agreement of plus disease diagnosis in retinopathy of prematurity. , 2007, Archives of ophthalmology.

[5]  Deniz Erdogmus,et al.  Plus Disease in Retinopathy of Prematurity: Improving Diagnosis by Ranking Disease Severity and Using Quantitative Image Analysis. , 2016, Ophthalmology.

[6]  Zheen Zhao,et al.  A PILOT STUDY USING ROPtool TO MEASURE RETINAL VASCULAR DILATION , 2009, Retina.

[7]  J. Català Mora,et al.  Computer-automated quantification of plus disease in retinopathy of prematurity , 2003 .

[8]  Domenico Lepore,et al.  Follow-up to Age 4 Years of Treatment of Type 1 Retinopathy of Prematurity Intravitreal Bevacizumab Injection versus Laser: Fluorescein Angiographic Findings. , 2017, Ophthalmology.

[9]  J. Flynn,et al.  Ophthalmoscopic monitoring of oxygen therapy in premature infants. Fluorescein angiography in acute retrolental fibroplasia. , 1971, American journal of ophthalmology.

[10]  John B. Shoven,et al.  I , Edinburgh Medical and Surgical Journal.

[11]  Darius M. Moshfeghi,et al.  Retinopathy of Prematurity Reactivated 28 Months after Injection of Ranibizumab. , 2019, Ophthalmology. Retina.

[12]  Darius M Moshfeghi,et al.  Chronic Vascular Arrest as a Predictor of Bevacizumab Treatment Failure in Retinopathy of Prematurity. , 2016, Ophthalmology.

[13]  S. T. Clay,et al.  Computerized analysis of retinal vessel width and tortuosity in premature infants. , 2008, Investigative ophthalmology & visual science.

[14]  Tueng T. Shen,et al.  Refractive Errors & Refractive Surgery Preferred Practice Pattern®. , 2018, Ophthalmology.

[15]  A. Hutchinson,et al.  Fluorescein Angiography in Retinopathy of Prematurity: Comparison of Infants Treated with Bevacizumab to Those with Spontaneous Regression. , 2019, Ophthalmology. Retina.

[16]  B J Kushner,et al.  Retrolental fibroplasia: I. Clinical observations. , 1977 .

[17]  James M. Brown,et al.  Automated Diagnosis of Plus Disease in Retinopathy of Prematurity Using Deep Convolutional Neural Networks , 2018, JAMA ophthalmology.

[18]  Verónica Bolón-Canedo,et al.  Dealing with inter-expert variability in retinopathy of prematurity: A machine learning approach , 2015, Comput. Methods Programs Biomed..

[19]  Graham E. Quinn,et al.  Atlas of fluorescein angiographic findings in eyes undergoing laser for retinopathy of prematurity. , 2011, Ophthalmology.

[20]  Deniz Erdogmus,et al.  Plus Disease in Retinopathy of Prematurity: A Continuous Spectrum of Vascular Abnormality as a Basis of Diagnostic Variability. , 2016, Ophthalmology.

[21]  William V Good,et al.  Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. , 2004, Transactions of the American Ophthalmological Society.

[22]  J. Flynn,et al.  Fluorescein angiography in retrolental fibroplasia: experience from 1969-1977. , 1979, Ophthalmology.

[23]  Michael F Chiang,et al.  Agreement among pediatric ophthalmologists in diagnosing plus and pre-plus disease in retinopathy of prematurity. , 2008, Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus.